GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Pharvaris N.V.
Shares of Pharvaris, a biotech company developing oral drugs to treat a rare genetic disease, are driven by news from its clinical programs. The price trajectory depends on regulatory decisions and trial results.
Share prices of companies in the market segment - Pharma immune
Shares of Pharvaris, a biotech developing oral drugs to treat a rare genetic disease, are driven by news from its clinical programs. We classify it as a Pharma-Immune company, and the chart below shows the dynamics of this entire segment.
Broad Market Index - GURU.Markets
Pharvaris is a Dutch biopharmaceutical company developing oral medications for the treatment and prevention of hereditary angioedema. It is a component of the GURU.Markets index. The chart below shows the US market. See how Pharvaris shares compare to the US market trend.
Change in the price of a company, segment, and market as a whole per day
PHVS - Daily change in the company's share price Pharvaris N.V.
The volatility of Pharvaris, a biopharmaceutical company, is measured by change_co. It reflects sensitivity to regulatory decisions and clinical trial results. This metric is important for formulas on System.GURU.Markets for analyzing the high-risk biotech sector.
Daily change in the price of a set of shares in a market segment - Pharma immune
Pharvaris N.V. is a biotech company. This chart demonstrates the extreme volatility of the sector. Comparison with PHVS, which focuses on rare disease treatments, helps to assess it as a high-risk, clinical-data-driven asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Pharvaris is a biopharmaceutical company developing drugs to treat rare diseases. Biotechnology is a volatile sector. The chart below shows average daily fluctuations in this sector, providing context for analyzing Pharvaris's stock performance.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Pharvaris N.V.
Pharvaris is a biopharmaceutical company. Its shares, like many in the sector, are volatile and react to news about clinical trials. These science-driven movements are part of the overall stock market landscape.
Annual dynamics of market capitalization of the market segment - Pharma immune
Pharvaris N.V. is a clinical-stage biotechnology company developing oral medications for the treatment of rare genetic diseases. Its stock price is entirely dependent on clinical trial results and regulatory decisions. The chart reflects the high risks and potential for breakthroughs in this field.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Pharvaris is a clinical-stage biotech whose value reflects the hopes of developing new drugs. Its shares exhibit extreme volatility and are completely disconnected from economic cycles. The company's chart isn't about business, but about binary events: the success or failure of clinical trials.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Pharvaris N.V.
Pharvaris, a biotech company developing oral medications for rare genetic diseases, shows sharp monthly fluctuations reflecting news about clinical trials and regulatory decisions, which is typical for companies at this stage.
Monthly dynamics of market capitalization of the market segment - Pharma immune
Pharvaris is a clinical-stage biotech company developing oral therapies for the treatment and prevention of hereditary angioedema (HAE), a rare disease. The chart below illustrates the overall dynamics of the biotech sector, where a focus on rare diseases could lead to breakthroughs.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Pharvaris N.V. is a clinical-stage biopharmaceutical company developing oral therapies for the treatment of hereditary angioedema (HAE). The company's future depends on the success of its clinical trials. The broader market chart serves only as a backdrop to understand how its potential to develop a convenient therapy for this rare disease impacted its stock price.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Pharvaris N.V.
The weekly performance of Pharvaris, a biopharmaceutical company developing oral medications for rare diseases, reflects the search for more convenient treatments. Share prices are responding to clinical data and regulatory decisions that could change the lives of patients.
Weekly dynamics of market capitalization of the market segment - Pharma immune
Biotech focused on rare diseases is a sector where weekly performance depends on clinical data and regulatory decisions. The search for oral alternatives to injections is a common trend. The chart illustrates this backdrop, which can be used to evaluate the Pharvaris platform.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Pharvaris is a biotech company developing drugs to treat rare genetic diseases. Shares of such innovative companies often move independently of the market. This chart will help you understand: is Pharvaris living in its own world of clinical trials, or is the overall market environment influencing its stock price?
Market capitalization of the company, segment and market as a whole
PHVS - Market capitalization of the company Pharvaris N.V.
Pharvaris's market capitalization chart tells the volatile story of a biotech company developing oral drugs for the treatment of hereditary angioedema. Its dynamics reflect both encouraging clinical data and regulatory hurdles from the FDA. Its trajectory tells the story of the struggle to bring a more convenient treatment for a rare disease to market.
PHVS - Share of the company's market capitalization Pharvaris N.V. within the market segment - Pharma immune
Pharvaris is a biotech company developing oral medications for the treatment of a rare genetic disorder, hereditary angioedema. Its market share reflects its potential. The chart shows how the company is striving to offer patients a more convenient alternative to existing injectable treatments.
Market capitalization of the market segment - Pharma immune
Pharvaris is a biotech company developing oral medications for the treatment of a rare genetic disorder, hereditary angioedema. The chart below shows the market capitalization of this sector. Its dynamics serve as a backdrop for the company's efforts to offer patients a more convenient alternative to injections.
Market capitalization of all companies included in a broad market index - GURU.Markets
Pharvaris is a company developing oral medications for the treatment of hereditary angioedema. Its market capitalization is driven by its focus on convenient tablet-based therapy. The chart below shows the weighting of biotech companies improving patients' quality of life.
Book value capitalization of the company, segment and market as a whole
PHVS - Book value capitalization of the company Pharvaris N.V.
Pharvaris's book value is its capital invested in clinical trials of oral medications for the treatment of a rare genetic disease, hereditary angioedema. This is a tangible, scientific foundation for improving patients' quality of life. How has this asset changed? The chart below shows its dynamics.
PHVS - Share of the company's book capitalization Pharvaris N.V. within the market segment - Pharma immune
Pharvaris is a biopharmaceutical company working on a treatment for hereditary angioedema, which requires research laboratories. The chart shows the share of these tangible assets in the sector, reflecting the physical foundation of its scientific work.
Market segment balance sheet capitalization - Pharma immune
Developing drugs to treat rare hereditary diseases, as the BCap_Seg chart for biotech shows, is a science-intensive endeavor. Pharvaris operates in this environment. Its assets are intellectual property and research data, not manufacturing capacity. It's a business at the forefront of science.
Book value of all companies included in the broad market index - GURU.Markets
Pharvaris' book value represents capital invested in clinical trials and intellectual property protection for its drugs for rare genetic diseases. It reflects a financial foundation that, if successful, will translate into the production of tangible and life-saving medications.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Pharvaris N.V.
Pharvaris is another clinical-stage biotech. Its MvsBCap story will be similar to other companies in the sector: its book value is minimal, and its market capitalization is driven by investor hopes for the success of its experimental treatment. The price chart will be highly volatile, driven by news about clinical trials and regulatory decisions.
Market to book capitalization ratio in a market segment - Pharma immune
Pharvaris N.V. is a biopharmaceutical company focused on the treatment of hereditary angioedema. Its valuation is entirely dependent on the success of its drug candidates. The chart shows the high premium the market places on its scientific potential.
Market to book capitalization ratio for the market as a whole
Pharvaris N.V. is a company developing oral medications for the treatment of rare genetic diseases. Its market valuation reflects the company's hopes that its developments will prove successful in clinical trials and transform the lives of patients. This is a classic example of investing in science rather than tangible assets.
Debts of the company, segment and market as a whole
PHVS - Company debts Pharvaris N.V.
Pharvaris, a clinical-stage biopharmaceutical company, is dedicating all of its raised capital to developing oral drugs for rare genetic diseases. Until commercialization, its survival depends on effective financial management. This chart illustrates how the company is funding its long and capital-intensive journey to drug discovery.
Market segment debts - Pharma immune
Pharvaris N.V. is a clinical-stage biopharmaceutical company specializing in the treatment of a rare genetic disease, hereditary angioedema. Funding R&D is its primary focus. This chart shows how the company manages its financial resources during the long process of developing and approving a new drug.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Pharvaris N.V.
Pharvaris N.V. is a biopharmaceutical company developing oral medications for the treatment of rare genetic diseases. The chart shows its financial structure. For a company in the R&D stage, raising debt is a bold move. Its level reflects the market's assessment of the likelihood of success of its drugs and its willingness to bear high risks for the sake of potentially high returns.
Market segment debt to market segment book capitalization - Pharma immune
Pharvaris N.V. is a pharmaceutical company developing treatments for rare genetic diseases. This industry-specific chart reflects how the sector as a whole finances the long and expensive path from idea to regulatory approval. It provides context for assessing the company's financial strategy and the risks inherent to its niche.
Debt to book value of all companies in the market
Pharvaris N.V. is a biotech company operating at the cutting edge of science. This chart reflects the overall risk appetite in the economy. For a company burning capital for future discoveries, it helps understand how its risky funding model compares to the overall market conditions and investors' willingness to wait.
P/E of the company, segment and market as a whole
P/E - Pharvaris N.V.
This chart of Pharvaris N.V., a company developing drugs for a rare genetic disease, shows how investors evaluate its scientific potential. The values reflect not current revenues, but the belief that a single successful drug could generate billions in sales and completely transform the company's fortunes.
P/E of the market segment - Pharma immune
This chart shows the average P/E for the biopharmaceutical industry, where Pharvaris develops drugs for rare diseases. The sector's very high average valuation suggests that investors are paying for hope. This metric provides context for assessing the market's perception of the potential of Pharvaris's developments.
P/E of the market as a whole
Pharvaris N.V. is a biopharmaceutical company developing oral inhibitors for the treatment and prevention of hereditary angioedema (HAE) attacks. This is a potentially market-changing approach. This biotech sentiment chart helps understand how the market views Pharvaris's chances of success in the competitive yet lucrative rare disease niche.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Pharvaris N.V.
Pharvaris N.V. is a biopharmaceutical company focused on developing oral medications for the treatment of a rare genetic disorder, hereditary angioedema. The chart shows investor expectations, which hinge on the success of clinical trials and the potential of its drugs to disrupt a market dominated by injections.
%20P%2FE%20Pharvaris%20N.V.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Pharvaris-N.V.&v=1772624620801 "Chart of the company's future (projected) P/E Pharvaris N.V.")
Future (projected) P/E of the market segment - Pharma immune
Pharvaris N.V. is a biopharmaceutical company focused on developing oral therapies for the treatment of a rare genetic disorder, hereditary angioedema. The chart compares Pharvaris's future profitability expectations with those of its sector. It helps understand how optimistic the market is about its developments.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-immune&v=1772624620813 "Future (projected) P/E graph of the market segment - Pharma immune")
Future (projected) P/E of the market as a whole
Pharvaris N.V. is a clinical-stage biopharmaceutical company developing oral therapies for the treatment of a rare genetic disorder, hereditary angioedema. This market sentiment chart shows how much investors are prepared to bear when investing in companies targeting orphan diseases.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772624620818 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Pharvaris N.V.
Pharvaris N.V. is a clinical-stage biopharmaceutical company focused on developing oral therapies for rare genetic diseases such as hereditary angioedema. This chart reflects its current clinical trial expenses, which are a necessary step toward potential future profitability.
Profit of companies in the market segment - Pharma immune
Pharvaris N.V. is a biopharmaceutical company developing oral medications for the treatment of rare genetic diseases, such as hereditary angioedema. This chart shows the overall profitability of the orphan disease niche, where innovative treatment approaches, such as switching from injections to tablets, can radically change the market.
Overall market profit
Pharvaris N.V. is a biopharmaceutical company focused on treating rare genetic diseases. Its performance and value are determined by clinical trial success, not by the economic outlook. The dynamics in this chart do not affect demand for life-saving medications, making the company unaffected by general market cycles.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Pharvaris N.V.
Pharvaris N.V. is a biopharmaceutical company focused on developing oral therapies for the treatment of a rare genetic disorder, hereditary angioedema. Future profits are dependent on clinical success and competition. This chart shows analyst expectations regarding the potential of its innovative treatment approach.
%20profit%20of%20the%20company%20Pharvaris%20N.V.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Pharvaris-N.V.&v=1772624620905 "Graph of future (projected) profit of the company Pharvaris N.V.")
Future (predicted) profit of companies in the market segment - Pharma immune
Pharvaris N.V. is a biopharmaceutical company developing oral medications for rare diseases such as hereditary angioedema. The company's goal is to offer patients a more convenient alternative to injections. This chart shows revenue expectations for the immunopharmaceuticals sector, providing context for evaluating Pharvaris' innovative approach.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-immune&v=1772624620930 "Graph of future (predicted) profits of companies in a market segment - Pharma immune")
Future (predicted) profit of the market as a whole
Pharvaris N.V. is a biopharmaceutical company developing oral therapies for the treatment of rare genetic diseases. Its prospects depend on success in research and development. The overall economic environment, reflected in this chart, influences the investment climate in the biotechnology sector, which influences Pharvaris's funding.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772624620968 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Pharvaris N.V.
Pharvaris N.V. is a clinical-stage biopharmaceutical company treating a rare genetic disorder, hereditary angioedema. It has no revenue yet. This chart is an indicator of investor confidence in its scientific approach and the potential of its future drug.
P/S market segment - Pharma immune
Pharvaris is a clinical-stage biopharmaceutical company focused on developing oral therapies for the rare genetic disorder hereditary angioedema (HAE). Their innovations have the potential to significantly improve the lives of patients. This chart reflects the average revenue estimate for the sector, which helps assess the potential of Pharvaris' developments.
P/S of the market as a whole
Pharvaris N.V. is a biopharmaceutical company focused on developing oral therapies for the treatment of rare genetic diseases, such as hereditary angioedema. This chart shows that the valuation of such companies is based on the potential of their innovative treatments, which contrasts sharply with the average market valuation based on revenue.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Pharvaris N.V.
Pharvaris N.V. is a biopharmaceutical company focused on developing oral therapies for the treatment of a rare genetic disorder, hereditary angioedema. Estimating future revenue is crucial for the company, reflecting investor expectations for the success of clinical trials and the potential of its drugs to change the standard of care for this disease.
%20P%2FS%20Pharvaris%20N.V.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Pharvaris-N.V.&v=1772624621015 "The graph of the company's future (projected) P/S Pharvaris N.V.")
Future (projected) P/S of the market segment - Pharma immune
Pharvaris N.V. is a biopharmaceutical company developing oral bradykinin inhibitors for the treatment and prevention of hereditary angioedema (HAE). This chart shows how investors view the company's future revenues relative to the pharmaceutical sector. It demonstrates the market's belief that the convenient oral formulation of the drug will capture significant market share from its injectable counterparts.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20immune&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-immune&v=1772624621029 "Future (projected) P/S market segment graph - Pharma immune")
Future (projected) P/S of the market as a whole
Pharvaris N.V. is another clinical-stage biotech company working on treatments for rare genetic diseases. Its value is based on expectations of future success. This chart reflects revenue projections for existing businesses, while Pharvaris represents the potential to create entirely new markets.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772624621036 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Pharvaris N.V.
This figure is for Pharvaris N.V., a biopharmaceutical company developing oral medications for the treatment of hereditary angioedema. Because its products are in clinical trials, there is no commercial revenue. Any revenue reflected in the chart is likely related to licensing agreements or grants.
Sales of companies in the market segment - Pharma immune
Pharvaris N.V. is a biotechnology company specializing in the development of oral therapies for the treatment of hereditary angioedema (HAE). Like many clinical-stage companies, it does not yet have sales revenue. Its future revenue will depend on the successful commercialization of its innovative treatments for this rare disease.
Overall market sales
Pharvaris N.V. is a clinical-stage company developing oral therapies for the treatment of rare genetic diseases. Its future is determined by scientific data and regulatory decisions. This chart, reflecting macroeconomic trends, reveals little about Pharvaris's prospects, as its value is created in the laboratory and measured by its potential to improve patients' lives.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Pharvaris N.V.
Pharvaris N.V. is a biopharmaceutical company focused on developing oral therapies for the treatment of a rare genetic disorder, hereditary angioedema. The company's future revenue is entirely dependent on the success of clinical trials and commercialization. This chart reflects analyst forecasts for Pharvaris' potential market size and share.
%20sales%20of%20the%20company%20Pharvaris%20N.V.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Pharvaris-N.V.&v=1772624621173 "Schedule of future (projected) sales of the company Pharvaris N.V.")
Future (projected) sales of companies in the market segment - Pharma immune
Pharvaris N.V. is a biopharmaceutical company developing oral therapies for the treatment of hereditary angioedema. This chart shows the outlook for the immunology sector. Is the market for rare disease drugs growing, creating opportunities for innovative therapies? This reflects a general trend in the industry.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-immune&v=1772624621208 "Schedule of future (projected) sales of companies in the market segment - Pharma immune")
Future (projected) sales of the market as a whole
Pharvaris N.V. is a biopharmaceutical company developing oral medications for the treatment of rare genetic diseases. The company's success depends on clinical trial results and regulatory approval. General economic cycles, as shown in this chart, do not affect patient demand for effective treatments for their conditions.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772624621210 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Pharvaris N.V.
Pharvaris N.V. is a biopharmaceutical company developing oral medications for the treatment of hereditary angioedema and other rare diseases. This chart shows its financial trajectory during clinical trials. Profitability depends on the success of the trials and potential regulatory approval of drugs that could significantly improve patients' quality of life.
Market segment marginality - Pharma immune
Pharvaris N.V. is a clinical-stage biotechnology company focused on developing oral therapies for the treatment of rare genetic diseases. Its financial performance is determined entirely by research and development (R&D) expenditures. This chart reflects the current expense structure, with future profitability dependent on the success of clinical trials and regulatory approvals.
Market marginality as a whole
Pharvaris N.V. is a biopharmaceutical company focused on treating rare genetic diseases. Its market capitalization and future depend on progress in clinical trials. This total return chart reflects the overall market risk appetite, which is critical for attracting the funding needed to continue expensive development.
Employees in the company, segment and market as a whole
Number of employees in the company Pharvaris N.V.
Pharvaris is a biotech company developing oral therapies for a rare genetic disease. Its small team of scientists and clinical development specialists is its greatest asset. This graph shows how the team grows as its candidates progress through various phases of clinical trials in Europe and the US.
Share of the company's employees Pharvaris N.V. within the market segment - Pharma immune
Pharvaris N.V. is a clinical-stage company developing oral medications for the treatment of rare genetic diseases such as hereditary angioedema. Its team consists of scientists and physicians. This chart shows the company's market share in the biotech industry, a measure of its progress in clinical trials and the scale of its research activities.
Number of employees in the market segment - Pharma immune
Pharvaris N.V. is a clinical-stage biopharmaceutical company developing oral bradykinin inhibitors for the treatment of hereditary angioedema and other conditions. The chart illustrates employment in the immunopharmaceutical sector. The development of a convenient oral drug could dramatically improve the quality of life for patients using injections.
Number of employees in the market as a whole
Pharvaris is a biotech company developing oral medications for rare genetic diseases. The growth of its research team, compared to the overall workforce in this chart, is a marker of progress in clinical trials. This is a story about how investment in research creates highly skilled jobs in the pharmaceutical industry.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Pharvaris N.V. (PHVS)
Pharvaris is a biotech company. This chart shows how the market values their scientific potential. Their entire value could be captured in a single promising development. Their per-employee market cap could be extremely high, reflecting not current sales but investor hopes for a future breakthrough in treating rare diseases.
%20of%20the%20company%20Pharvaris%20N.V.%20(PHVS)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Pharvaris-N.V.-PHVS&v=1772624621475 "Chart of market capitalization per employee (in thousands of dollars) of the company Pharvaris N.V. (PHVS)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma immune
Pharvaris (PHVS) is a clinical-stage biotech developing oral medications (B2 inhibitors) for the treatment of hereditary angioedema (HAE). This chart shows the industry average cost per employee. It helps assess how the market views their R&D portfolio and the potential of their drugs compared to competitors.
%20by%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-immune&v=1772624621506 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma immune")
Market capitalization per employee (in thousands of dollars) for the overall market
Pharvaris N.V. is another biotech company focused on treating rare genetic diseases. Its market capitalization reflects the potential of its R&D pipeline rather than its current financial results. The high valuation per employee in this chart is typical for an industry where a small scientific team can create a multi-billion-dollar product.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772624621556 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Pharvaris N.V. (PHVS)
Pharvaris N.V. is another clinical-stage company developing treatments for rare inherited diseases. Like Dianthus, this chart reflects R&D workload rather than current profitability. It shows how much capital the company invests in each of its researchers, with the expectation that their discoveries will lead to the development of a sought-after drug.
%20Chart%20Pharvaris%20N.V.%20(PHVS)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Pharvaris-N.V.-PHVS&v=1772624621591 "Company Profit Per Employee (in thousands of dollars) Chart Pharvaris N.V. (PHVS)")
Profit per employee (in thousands of dollars) in the market segment - Pharma immune
Pharvaris (PHVS) is an R&D biotech company (rare diseases - NAO). This chart shows the benchmark for "Immune Pharma" (R&D). The average profit per employee in this sector (venture R&D) is *negative*. This benchmark reflects the "burning" of money in the hopes of one or two mega-successes. The entire sector is an R&D race, spending billions on elite scientists.
%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-immune&v=1772624621629 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma immune")
Profit per employee (in thousands of dollars) for the market as a whole
Pharvaris N.V. is a clinical-stage biotechnology company specializing in the treatment of hereditary angioedema. It's an R&D company. This chart shows the company's capital burn rate: the operating loss per research team developing a new drug through clinical trials.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772624621663 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Pharvaris N.V. (PHVS)
Pharvaris N.V. is a clinical-stage biopharmaceutical company. A lack of revenue per employee at this stage is the norm. This metric reflects future prospects: if the developed drug is commercialized, its high price will lead to very high revenue per employee, monetizing years of research.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Pharvaris-N.V.-PHVS&v=1772624621731 "Sales chart per company employee Pharvaris N.V. (PHVS)")
Sales per employee in the market segment - Pharma immune
Pharvaris N.V. is a clinical-stage biotechnology company developing oral (tablet-based) drugs for the treatment of rare diseases, particularly hereditary angioedema. This is R&D. This chart shows the average output in the sector. For PHVS, this is also a leading indicator of the effectiveness of their research team in creating new drugs.
Sales per employee for the market as a whole
Pharvaris is a biotechnology company developing oral medications (in tablet form) for the treatment of rare diseases such as hereditary angioedema. Like other clinical-stage companies, Pharvaris does not yet have commercial revenue. This reflects the company's intensive research phase.
Short shares by company, segment and market as a whole
Shares shorted by company Pharvaris N.V. (PHVS)
Pharvaris (PHVS) is another biotech company focused on treating hereditary angioedema (a competitor of BioCryst). This chart shows the volume of short positions. Short sellers may be betting that the company's drug will prove unsafe (the company has had issues with the FDA) or less effective than existing treatments.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Pharvaris-N.V.-PHVS&v=1772624621849 "Short Shares Chart for the Company Pharvaris N.V. (PHVS)")
Shares shorted by market segment - Pharma immune
Pharvaris (PHVS) is a biopharmaceutical company developing oral therapies for the treatment of hereditary angioedema (HAE). This chart shows the total short position in the biotech sector. It reflects investor concerns about the highly competitive HAE market and regulatory risks.
Shares shorted by the overall market
Pharvaris (PHVS) is a clinical-stage biotech (immunology). This indicator (`Short_All`) is a mirror of market fear. When it rises, investors panic and dump risk, especially unprofitable biotechs. This pessimism, visible on the chart, deprives PHVS of access to the capital needed for expensive trials.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Pharvaris N.V. (PHVS)
Pharvaris (PHVS) is a biotech company developing oral (tablet) drugs for the treatment of the rare genetic disease hereditary angioedema (HAE). This chart measures hype. It shows "overbought" (above 70) on news of FDA clinical restrictions being lifted or "oversold" (below 30) on news of trial delays.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Pharvaris-N.V.-PHVS&v=1772624621914 "RSI 14 indicator chart for the company's stock Pharvaris N.V. (PHVS)")
RSI 14 Market Segment - Pharma immune
Pharvaris (PHVS) is a biotech company developing oral (tablet) drugs for the treatment of a rare hereditary angioedema (HAE). The RSI_14_Seg for "Pharma immune" shows whether the biotech segment is overheated. The chart helps us understand: is PHVS's volatility due to its R&D or general hype?
RSI 14 for the overall market
Pharvaris (PHVS) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast PHVS (Pharvaris N.V.)
Pharvaris is a biotech company focused on the treatment of hereditary angioedema (HAE). Their goal is to develop an oral drug (pill) to prevent attacks. This chart shows the average analyst forecast, which is highly dependent on the progress of clinical trials and regulatory decisions (e.g., the FDA) regarding their drugs.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-PHVS-Pharvaris-N.V.&v=1772624621996 "A chart showing analyst consensus forecasts for the expected stock price. PHVS (Pharvaris N.V.)")
The difference between the consensus estimate and the actual stock price PHVS (Pharvaris N.V.)
Pharvaris is a biotech company developing oral (tablet-based) drugs for the treatment of a rare genetic disorder, hereditary angioedema (HAE). This chart shows the difference between the market's current valuation of the company and the analyst consensus price target. This reflects their confidence in the success of these developments.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-PHVS-Pharvaris-N.V.&v=1772624622020 "A chart showing the difference between the consensus forecast and the actual stock price. PHVS (Pharvaris N.V.)")
Analyst consensus forecast for stock prices by market segment - Pharma immune
Pharvaris is a biopharmaceutical company developing oral (tablet) therapies for the treatment of hereditary angioedema (HAE). This chart shows general expectations for the rare disease sector. It reflects whether experts believe oral medications can replace injections in this niche market.
Analysts' consensus forecast for the overall market share price
Pharvaris (PHVS) is a clinical-stage biopharmaceutical company focused on treating hereditary angioedema, a rare immune disorder. This chart shows the overall market risk appetite, reflecting investors' willingness to invest in long, expensive R&D projects with uncertain outcomes.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Pharvaris N.V.
Pharvaris is a clinical-stage biotech focused on a single goal: developing an oral (tablet-based) treatment for hereditary angioedema (HAE). This graph represents a pure R&D bet, likely reflecting investors' confidence in their clinical data and their ability to compete with existing (injectable) treatments.
AKIMA Market Segment Index - Pharma immune
Pharvaris (PHVS) is a clinical-stage biotech focused on HAE; the company (a competitor of BioCryst) is developing a novel oral (tablet) drug for the treatment of HAE (angioedema) attacks. This summary metric evaluates R&D. The graph shows the average value for the segment. This is a benchmark: how does this niche (HAE) R&D focus of PHVS differentiate it from the average pharma company?
The AKIM Index for the overall market
Pharvaris is a biopharmaceutical company developing oral medications for the treatment of hereditary angioedema (HAE). This chart, which reflects the market average, provides a macro backdrop. It helps assess how this innovative company, which aims to replace injections with pills, compares to overall economic trends.
